<- Go Home
Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
Market Cap
AUD 140.0M
Volume
304.4K
Cash and Equivalents
AUD 7.3M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-AUD 1.3M
Profit Margin
1081.42%
52 Week High
AUD 0.63
52 Week Low
AUD 0.12
Dividend
N/A
Price / Book Value
18.14
Price / Earnings
-24.32
Price / Tangible Book Value
18.14
Enterprise Value
AUD 132.8M
Enterprise Value / EBITDA
N/A
Operating Income
-AUD 4.0M
Return on Equity
90.37%
Return on Assets
-49.16
Cash and Short Term Investments
AUD 7.3M
Debt
N/A
Equity
AUD 7.2M
Revenue
AUD 118.9K
Unlevered FCF
-AUD 1.8M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium